Latest Clinical & Research News
Specialty: Oncology
The androgen-receptor inhibitor enzalutamide already has established benefit in castration-resistant prostate cancer. Now the randomized phase III trial ENZAMET is exploring the impact of adding enzalutamide to testosterone suppression for metastatic hormone-sensitive prostate cancer (mHSPC). Interim analysis showed significantly prolonged overall survival with less cancer progression.
Read More
A study presented at the 2019 ASCO Annual Meeting showed that radiation therapy prior to surgery does not reduce the rate of local recurrence among most patients with retroperitoneal sarcoma (RPS). Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) was the only U.S. center to participate in the European trial of 256 patients.
Read More
Dana-Farber Cancer Institute physician-researcher Ian E. Krop, MD, PhD, has uncovered a promising way to identify patients who will respond well to certain adjuvant therapies for treating HER2+ breast cancer. He presented the findings of his biomarker analysis at the 2019 ASCO Annual Meeting.
A new study featured on the cover of the March issue of Nature Medicine offers hope for treating patients with glioblastoma. In a small randomized controlled clinical trial, patients with recurrent glioblastoma lived nearly twice as long if they received an immunotherapy drug prior to and following surgery, compared to patients who only received the drug after surgery.
Read More
For the first time, cancer patients in New England will have a cutting-edge option for radiation treatment of soft-tissue tumors. The new MR-Guided Radiation Therapy (MR-RT) treatment at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), launching this summer, will give physicians real-time, pinpoint accuracy for radiation planning and treatment.
Read More
When diagnosed and treated in its early stages, endometrial cancer is largely curable. However, for the 10 to 15 percent of patients diagnosed with late-stage disease, standard therapy does not lead to a cure.
Read More
Over the past two decades, the Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) has become a national leader in the care of patients with hereditary gastrointestinal cancers, from Lynch syndrome to polyposis syndromes.
Read More
Chimeric antigen receptor T (CAR T) cell therapy has become an important tool in the treatment of relapsed and refractory malignancy. However, it is associated with significant and unique neurological toxicities.
A multidisciplinary team of clinicians at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) are among the first in the nation to study this issue as a team prospectively; their findings are about to be published in the journal Brain.
Read More
Colorectal cancer remains a major health problem in the United States. It’s the third most common type of cancer and the second leading cause of cancer death.
While the incidence of colorectal cancer is decreasing somewhat in the population, it has increased by 51 percent in people under the age of 50. This trend is expected to continue, with an estimated 90 percent increase in colon cancer incidence and 124 percent increase in rectal cancer incidence by 2030.
Read More
Elizabeth A. Mittendorf, MD, PhD, a breast cancer surgeon and international leader in breast cancer vaccines, recently joined Brigham and Women’s Hospital (BWH) from the MD Anderson Cancer Center in Houston, where her research focused on vaccines that target the HER2 protein expressed on many breast tumors. At the Brigham, her work focuses on advancing our understanding of breast cancer immunotherapies.